Analyst Tim Anderson of Bank of America Securities reiterated a Buy rating on Gilead Sciences (GILD – Research Report), retaining the price target of $126.00.
Tim Anderson’s rating is based on Gilead Sciences’ strong long-term growth prospects and its relatively low exposure to tariffs compared to its peers. The company’s financial performance in the first quarter was solid, with earnings per share exceeding both consensus and internal expectations. Furthermore, Gilead’s guidance for 2025 remains unchanged, indicating stability in its future outlook.
Investor interest is particularly focused on the upcoming launch of lenacapavir for HIV prevention, which could significantly impact the company’s revenue. Despite some uncertainties regarding the uptake of this new drug, Gilead’s existing high-margin product, Biktarvy, is expected to continue driving growth. Additionally, the company’s strategic positioning in the biopharmaceutical sector, with fewer patent expirations in the near term, supports a positive outlook. These factors collectively contribute to the Buy rating with a price objective of $126.00 USD.
Anderson covers the Healthcare sector, focusing on stocks such as Gilead Sciences, Eli Lilly & Co, and Pfizer. According to TipRanks, Anderson has an average return of 8.8% and a 69.86% success rate on recommended stocks.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $125.00 price target.